NCT05465954: Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma
- State
- Under way
- Phase
- Phase 2
- People
- 53 taking part
- Started
- 24 Jan 2023
- Primary completion
- 2 Sep 2026
- Arms
- Treatment (efineptakin alfa, pembrolizumab)
- Results
- None posted
- 20 Jul 2022: Trial registered
- 24 Jan 2023: Trial started